Dyne Therapeutics, Inc. 8-K

What Happened

• Dyne Therapeutics, Inc. (DYN) filed a Form 8-K on January 12, 2026 (Item 2.02) saying it expects to report approximately $1.1 billion in cash, cash equivalents and marketable securities as of December 31, 2025. The company has not completed its full financial close for Q4 and fiscal year 2025 and the figure is preliminary and unaudited. The company’s independent auditor has not audited or reviewed this estimate and expresses no assurance on it. The company also made a presentation available to investors (Item 7.01; Exhibit 99.1) dated January 12, 2026.

Key Details

• Estimated cash, cash equivalents and marketable securities: approximately $1.1 billion (as of Dec 31, 2025).
• Disclosure date / filing: January 12, 2026 (Form 8-K).
• Status of figure: preliminary, unaudited, management estimate subject to completion of financial closing procedures; independent auditor has not reviewed.
• Investor material: presentation filed as Exhibit 99.1 (Regulation FD disclosure) and made available the same day.

Why It Matters

• Cash position is a key liquidity metric for biotech companies: a ~$1.1B preliminary balance gives investors a snapshot of Dyne’s available resources to fund operations, R&D and clinical programs through the near term.
• Because the figure is preliminary and unaudited—and full Q4/FY2025 results are not yet finalized—investors should treat it as an estimate that could change when year-end financials are completed and audited disclosures are released.
• The filed presentation may provide additional operational and strategic context; investors should review the Exhibit 99.1 slides and await the finalized financial statements for a complete view of quarterly and annual results.